

GENERICS AND BIOSIMILARS

GRx+ Biosims™

EXPLORING THE FUTURE OF
GENERICS AND BIOSIMILARS

#GRXBIOSIMS

What's New with Electronic Submissions?

CDER/OBI

October 28, 2025

OBI – What's New with Electronic Submissions

- eCTD v4.0
- eCTD General Update
- CDER NextGen Portal
- Generic Drug Structured Assessment – Bioequivalence (GDSA-BE)

FDA eCTD v4.0 Activities

- CBER/CDER Supporting eCTD v4.0 as of September 16, 2024
  - Federal Register Notice – published 9/16/24
  - For a listing of eCTD v4.0 Implementation Guides, Specifications, Validations, Technical Conformance Guide, and Supportive Files, refer to the eCTD Submission Standards for eCTD v4.0 and Regional M1

(fig. 2)

- eCTD Guidance – Revision 8
  - Updated hyperlinks
  - Added references to eCTD v4.0
- FDA Data Standards Catalog
  - Added eCTD v4.0
- FDA Study Data Technical Conformance Guide
  - Added eCTD v4.0 related references



eCTD Submission Standards for eCTD v4.0 and Regional M1

Share | Post | Linkedin | Email | Print

The table below lists all the documents and supportive files applicable to eCTD submissions to CDER and CBER.

Version History

Submission Standards for eCTD v4.0

Validation Tools and Electronic Submission Validation Criteria in Use

Version History

9/16/2024 - Date Support Begins Added

Submission Standards for eCTD v4.0

Search: 9/16 Export Excel Show All entries

Use/Regulatory Reference	Type	Version	Implementation Guide Reference	Date Support Begins	Date Requirement Begins	Date Support Ends
eCTD v4.0 Comprehensive Table of Contents Headings and Hierarchy	Documentation and Resources	2.1		9/16/2024		
eCTD v4.0 Module 1 Implementation Package (Implementation Guide, CV)	Documentation and Resources	1.5.1		9/16/2024		
eCTD v4.0 Technical Conformance Guide	Documentation and Resources	1.3	Final Guidance for Industry: Providing Regulatory Submissions in Electronic Format – eCTD Specifications	9/16/2024		
ICH eCTD v4.0 Implementation Package (IG, CV, Genericode Files, and Schema Files)	Documentation and Resources	1.5	M8 eCTD: Electronic Common Technical Document Specifications	9/16/2024		
Specifications for eCTD v4.0 Validation Criteria	Documentation and Resources	1.3.1		9/16/2024		

Showing 1 to 5 of 5 entries (filtered from 14 total entries) Previous 1 Next

Fig. 2 – Snippet of eCTD Submission Standards for eCTD v4.0 and Regional M1

FDA eCTD v4.0 Implementation Strategy

- Initial release/acceptance for new applications in eCTD v4.0 *(fig. 3)*
  - Allows for development of eCTD v4.0 applications across regions
  - CBER/CDER support started 9/16/24
  - Sample submissions can be sent to CDER ESUB for technical feedback
- Future phases
  - Transition of current applications (Forward Compatibility)
  - Two-way communication



Electronic Common Technical Document (eCTD) v4.0

Share | Post | Linkedin | Email | Print

The documentation and links on this webpage provide information on how to submit eCTD v4.0-based electronic submissions to the Center for Drug Evaluation and Research (CDER) or the Center for Biologics Evaluation and Research (CBER).

FDA eCTD v4.0 Implementation Status

CDER and CBER are accepting new regulatory applications in eCTD v4.0 format as of September 16, 2024. More information can be found on the eCTD page.

Future implementation phases will address forward compatibility for existing v3.2.2 applications and two-way communication.

eCTD Submission Standards

For a listing of eCTD v4.0 Implementation Guides, Specifications, Validations, Technical Conformance Guide, and Supportive Files, please refer to the eCTD Submission Standards for eCTD v4.0 and Regional M1.

Send a Sample v4.0 Submission to FDA

There is an optional process to submit a sample eCTD v4.0 and/or standardized data sample for feedback. Currently only new application samples will be evaluated. Future phases will include evaluation of forward compatibility. For information on the process of submitting a sample, please refer to Submit an eCTD v4.0 or Standardized Data Sample to the FDA.

Additional Resources: ICH eCTD v4.0 Step 4 – Implementation Package

The ICH eCTD v4.0 Implementation Package, regional Implementation timeline information, and related files are available for download from the ICH eCTD v4.0 Step 4 page.

To submit comments or questions on the ICH eCTD v4.0 Implementation Package please see the Change Control section on the ICH eCTD v4.0 page.

Fig. 3 – Snippet of FDA eCTD v4.0 web page

Technical Feedback on eCTD v4.0 Samples



- FDA CDER eSub team performs technical validation on the sample submission and reports back on validation errors and other technical issues
  - Find information about it here: Submit an eCTD v4.0 or Standardized Data Sample to the FDA | FDA *(Fig. 4)*

Fig. 4 – Snippet of FDA eCTD sample web page

eCTD v4.0 Resources

- ICH eCTD v4.0 Materials (https://www.ich.org/page/ich-electronic-common-technical-document-ectd-v40)
  - ICH eCTD v4.0 Implementation Package
  - Supplemental Documents for eCTD v4.0 Implementation Package
  - Regional Implementation Information & Regional Links
  - Change Control

- FDA eCTD v4.0 Regional Implementation Information

  (https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/electronic-common-technical-document-ectd-v40)
  - FDA eCTD v4.0 M1 Implementation Package
  - eCTD v4.0 Technical Conformance Guide
  - Link to ICH eCTD v4.0 webpage

- FDA Related Guidance and Specifications
  - eCTD Guidance – Revision 8 (https://www.fda.gov/media/135373/download)
  - FDA Data Standards Catalog (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-standards-catalog)
  - FDA Study Data Technical Conformance Guide (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/study-data-technical-conformance-guide-technical-specifications-document)

What's New in eCTD? (v3.2.2 and v4.0)

- CBER and CDER are accepting **new regulatory applications in eCTD v4.0 format as of September 16, 2024**.
  - More information can be found on the eCTD page
  - Samples can be submitted for feedback on eCTD v4 submissions

- Future implementation phases:
  - forward compatibility for existing v3.2.2 applications
  - two-way communication.

Region	Technical Pilot[1]	Implementation Dates[2]	Implementation Documents
FDA, United States	2022 - 2Q 2023 (Completed)	2024 (Voluntary) 2029 (Mandatory)	FDA, United States regional implementation page

This information will be updated biannually based on the progress of ongoing implementation activities.

[Updated in July 2025]

What's New in eCTD? (v3.2.2 and v4.0)

- 23 new values added for file tags/keywords
  - **effective for FDA use February 2025**
  - Valid Values v6.0
  - ICH Controlled Vocabulary
  - Study Data Technical Conformance Guide section 7.1.4 has more detail on how and when to use

```
    <!--  23 new values below added  v6.0  - May 2024   -->
    <valid-value realm="ich" value="csr_other"/>
    <valid-value realm="ich" value="hepatic-impairment-study"/>
    <valid-value realm="ich" value="renal-impairment-study"/>
    <valid-value realm="ich" value="drug-drug-interaction-study"/>
    <valid-value realm="ich" value="mass-balance-study"/>
    <valid-value realm="ich" value="population-pk-report"/>
    <valid-value realm="ich" value="population-pkpd-report"/>
    <valid-value realm="ich" value="pbpk-report"/>
    <valid-value realm="ich" value="pbbm-report"/>
    <valid-value realm="ich" value="qsp-report"/>
    <valid-value realm="ich" value="cp-general"/>
    <valid-value realm="ich" value="qt-clinical-study"/>
    <valid-value realm="ich" value="qt-invitro-study"/>
    <valid-value realm="ich" value="pd-invivo-study"/>
    <valid-value realm="ich" value="pd-invitro-study"/>
    <valid-value realm="ich" value="iscp"/>
    <valid-value realm="ich" value="isi"/>
    <valid-value realm="ich" value="study-data-reviewers-guide"/>
    <valid-value realm="ich" value="analysis-data-reviewers-guide"/>
    <valid-value realm="ich" value="weight-of-evidence"/>
    <valid-value realm="ich" value="animal-rule-efficacy"/>
    <valid-value realm="ich" value="animal-rule-natural-history"/>
    <valid-value realm="ich" value="nonstandard-safety-study"/>
    <!--  23 new values above added  v6.0  - May 2024  -->
  </file-tag>
</ectd:study-values>
```

			D	E
			Reference	Status
				Active
				Active
ich_document_type_78	mass balance study	Mass balance study to obtain quantitative information on drug absorption, distribution, metabolism, and elimination properties		Active
ich_document_type_79	population pk report	Report summarizing population pharmacokinetic (population PK) analyses conducted to inform drug development		Active
ich_document_type_80	population pkpd report	Report summarizing population pharmacokinetic/pharmacodynamic analyses conducted to inform drug development		Active
ich_document_type_81	pbpk report	Report summarizing physiologically-based pharmacokinetic analyses conducted to inform drug development		Active
ich_document_type_82	pbbm report	Report summarizing physiologically-based biopharmaceutics modelling conducted to inform recommendations on biopharmaceutics applications		Active
ich_document_type_83	qsp report	Report summarizing population quantitative systems pharmacology analyses conducted to inform drug development		Active
ich_document_type_84	cp general	Checklist document and clinical pharmacology table		Active
ich_document_type_85	qt clinical study	Stand-alone thorough QT studies or QT assessments	E14/S7B Q&As	Active

- File format spec
  - 9 new Modeling & Simulation file types added
  - Use of .zip and .html expanded for R packages

Top Reasons for ANDA eCTD Rejection



What is CDER NextGen Portal?

The CDER NextGen Portal serves as a comprehensive platform for collaboration and reporting, specifically designed to facilitate non-eCTD submissions. The portal allows sponsors to submit notifications, correspondence, and exempt human drug applications efficiently. This collaborative capability consistently reduces regulatory overhead for sponsors, academic institutions, research organizations, and small businesses.



Controlled Correspondence Metrics FY 25*

Submissions	Oct 24	Nov 24	Dec 24	Jan 25	Feb 25	Mar 25	Apr 25	May 25	Jun 25	July 25	FY 25
Controlled Correspondence	318	231	293	348	338	297	362	384	375	347	3293
Level 1	276	196	241	299	294	258	309	335	323	288	2819
Level 2	42	35	52	49	44	39	53	49	52	59	474

* As of 9/5/2025

Controlled Correspondence Metrics for FY 2025



* As of 9/22/2025

Generic Drug Structured Assessment – Bioequivalence (GDSA-BE)

OGD Structured Review Templates in NEXUS (Appian) – *Enterprise-level solution*

Modernization of drug review *from* unstructured narrative *to* structured data with dynamic and interactive collaboration capabilities utilizing an integrated system.



OGD Generic Drug Structured Assessment (GDSA) Development

- Stage I: Labeling Review Tool (LRT)
- Stage II: Bioequivalence Review Modules (GDSA-BE) *(March 2022 – Present)*

Challenges to Bioequivalence Assessment and Need for Modernization

Problem – Current Approach

- A freestyle narrative-based Bioequivalence(BE) assessment, which is in place for decades
- Assessors evaluate individual applications in relative isolation without fully assessing the wealth of information at FDA's disposal.
- Labor intensive tasks to process data, conduct data analysis, and extract and supply standard information to the review templates
- Created inconsistent review language and lack of standardization across BE reviews, inability to share prior knowledge and manage information

Solution – Time to Modernize

- **Generic Drug Structured Assessment – Bioequivalence (GDSA-BE)** has been conceptualized to enable efficient project management and streamlined review workflow along with the introduction of review automation, data analytics and knowledge management.
- A systematic approach to an efficient and consistent BE assessment which aids rapid and well-informed regulatory decision-making

Auto-Population and Auto Analysis of eCTD, PK/BE Data and IIG Data

- ❑ Auto-population of eCTD data in review template for solid Oral Dosage forms by BEAM tool
- ❑ Auto-analyze PK/BE data for two-way crossover study by BEAM tool
- ❑ Auto-fill data from FDA Mercado database resources into BE review inactive ingredients section and automate data analytics

Efficient Communication and Processes Between Assessors and PMs

- ❑ Enhanced communication with built-in comments features and footnote references
- ❑ Improved efficiency by incorporating track changes and version comparison features
- Persona–based notifications, task sequencing, etc. for in-time communication between assessors and PMs



Standardization and Consistency of Review Language

- ❑ Systematize and standardize review language in Executive Summary section
- ❑ Mapping BE deficiencies with the Letter to Applicant
- ❑ Enhanced consistent deficiency language usage by linking to a deficiency language library
- ❑ Knowledge management for BE deficiency database

Advanced Progress Monitoring and Quality of Reviews

"Data Discovery - Reviews" for Project Managers to track review progress using status, milestone dates, and field searches

- ❑ "My Tasks" for Assessors to monitor their assigned tasks by status and field searches
- ❑ “Validate” feature to ensure all required fields are completed prior to finalizing review to improve quality control of review
- ❑ Dynamic print templates for each finalized review



Please visit the Office of Generic Drugs(OGD) booth for more information on GDSA-BE.